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Summary
Background: Holter monitoring is routinely used
in patients referred for the evaluation of syncope,
but its diagnostic value in different patient groups
is unclear, as is its impact on device implantation
(pacemaker or cardioverter-defibrillator).
Aim: To determine the diagnostic yield of Holter
monitoring in the routine evaluation of syncope, and
its impact on subsequent device implantation.
Design: Retrospective record review.
Methods: We reviewed all Holter studies in patients
referred with syncope between 2000 and 2005.
Strict criteria were applied to determine whether
a study was diagnostic. The diagnostic value of
Holter monitoring (overall and in five subgroups:
age, gender, structural heart disease, ejection frac-
tion, medication) and its impact on the implantation
of devices, were determined.
Results: Of 4877 Holter studies, 826 were per-
formed in patients with syncope (age 72 15 years):
71 (8.6%) were considered to explain the syncope.
Structural heart disease, ejection fraction and age
were significant predictors of a diagnostic study
(all p<0.01), whereas gender and cardiac medica-
tion were not. A device was implanted in 33 patients
(4.4%) whose initial Holter did not explain their
syncope, after mean 7 months, whereas 45 patients
(5.4%) received a pacemaker based on the Holter
results (p¼ 0.32).
Discussion: The overall diagnostic yield of
Holter monitoring in the evaluation of syncope
was 8.6%, with dramatic differences between
subgroups. Our data suggest that the impact
of Holter monitoring on device implantation is
generally overestimated.
Introduction
Syncope, defined as a sudden temporary loss of
consciousness accompanied by a loss of postural
tone, is a problem often seen by physicians in
clinical practice.1 In the Framingham Heart Study,
11% of the subjects had at least one syncopal
episode during an observation period of 18 years.2
Syncope accounts for 1–3% of visits to emergency
departments and as much as 6% of hospital
admissions. The prevalence of syncope varies
significantly between different patient groups, and
may be as high as 25% in a nursing home popu-
lation aged 470 years.3–6 Vasovagal syncope has
a benign prognosis, whereas cardiac syncope can
be a predictor of serious disease, with a five-year
mortality approaching 50%.2 Arrhythmias are the
most common cardiac of cause syncope, and
include bradyarrhythmias (such as sinus node
dysfunction), atrioventricular conduction disorders,
atrial fibrillation with slow or rapid ventricular
response, and ventricular tachyarrhythmias.
The important issue when evaluating patients with
presumed syncope is to determine whether they
have in fact experienced syncope.7 As the majority
of syncopes occur unwitnessed, diagnostic evalua-
tion is often carried out because of presumed
syncope, and frequently includes Holter monitoring,
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among other tests. The overall diagnostic yield
of Holter monitoring reported in the literature is
1–20%.8–9 However, it strongly depends on the
population studied, a fact frequently not taken
into consideration when referring patients for
Holter monitoring.10 In addition, little is known
about its impact regarding the subsequent implanta-
tion of pacemakers and implantable cardioverter-
defibrillators (ICDs), and the effectiveness of this
procedure.
We analysed an unselected group of patients with
syncope referred for a single 24-h Holter monitoring
session, and determined the diagnostic yield of
Holter monitoring, with a focus on different patient
groups and the impact on device implantation.
Methods
The data for this study were collected between
January 2000 and December 2005, and stem from
both out-patient and in-patient services. All Holter
studies performed in patients due to syncope were
reviewed for significant arrhythmias as the cause of
syncope. Medical records of the patients were used
to obtain demographic data and details on medical
history, cardiac medication, echocardiography,
and on actions taken based on the results of Holter
monitoring. Holter studies were performed for 24 h
with a two-channel device (Schiller AG). A patient
was considered to have structural heart disease
if he had evidence of cardiomyopathy on echocar-
diography or had documented coronary artery
disease or myocardial infarction.
Findings on Holter studies were classified as
follows.
(i) A normal Holter study. Completely normal
studies or studies with arrhythmias of no
clinical significance, e.g. patients with occa-
sional premature atrial or ventricular contrac-
tions, patients with known atrial fibrillation
and appropriate rate control.
(ii) An abnormal Holter study unlikely to explain
syncope, e.g. bundle branch block, second-
degree AV block Mobitz type I or non-
sustained ventricular tachycardia (53 beats,
<30 seconds), which, in the absence of
depressed left ventricular ejection fraction
(LVEF), is a condition considered to have an
excellent prognosis.11
(iii) A Holter study considered to be diagnostic,
with one of the following arrhythmias during
monitoring that could be correlated to
syncope or presyncope: second-degree AV
block Mobitz type II or third degree AV block;
sinus pauses 53 s; atrial fibrillation with slow
ventricular response (<40 bpm while awake);
sustained ventricular tachycardia (430 s);
supraventricular tachycardia or atrial fibrilla-
tion at a rate of4175 bpm for430 s.
Based on this approach, the diagnostic value
of Holter monitoring, both overall and in five pre-
specified subgroups (age, gender, structural heart
disease, LVEF, medication), and its impact on the
implantation of permanent pacemakers and ICDs,
was determined.
In December 2006, a qualified study nurse
contacted all patients who had received a device
and who were still alive, to determine whether
further syncopal episodes had occurred during
follow-up.
Statistical analyses
All continuous variables were summarised as
means SD. Comparisons were made using the 2
statistic for categorical variables and a student’s
t-test for continuous variables. A p value <0.05 was
considered significant.
Results
Baseline characteristics
Of the 4877 Holter studies performed during
the study period, 826 (17%) were ordered for the
evaluation of patients with syncope. The mean SD
age of the patients was 72 15 years (range 19–96).
Female patients (n¼445, 75 15 years) were
significantly older than male patients (6916
years, p<0.0001). Data on demographic and
clinical characteristics are summarised in Table 1.
LVEF was available in 626 patients (76%); mean
value was 57% 10%. Almost half of the patients
(n¼ 375, 45%) had either evidence of structural
heart disease on echocardiography, documented
coronary artery disease or myocardial infarction.
Ischaemic heart disease was the most common
cause of structural heart disease (23%), followed by
hypertensive (12%), and valvular heart disease (6%).
Other structural heart diseases such as hypertrophic
and dilated cardiomyopathy were infrequent as
demonstrated in Figure 1. The high percentage of
patients with structural heart disease is also reflected
by the medication (Table 1). Only 69 patients (8%)
were without cardiac medication. The patients with
structural heart disease had a mean LVEF of
53% 12% (LVEF known in 338/375 patients,
90%). This was significantly lower (p<0.0001)
than in patients with no structural heart disease,
who had an LVEF of 61 5% (LVEF known in
288/451 patients, 64%).
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Results of Holter monitoring
Of the 826 Holter studies, 714 (86%) were classified
as completely normal. Forty-one (5%) were classi-
fied as abnormal, but unlikely to explain syncope
due to non-sustained ventricular tachycardia. In
40 of these 41, all available clinical information
warranted no further action. In the only patient with
non-sustained ventricular tachycardia and an ejec-
tion fraction of less than 40%, an electrophysiolo-
gical study was performed. A sustained ventricular
tachycardia was induced and an ICD implanted,
based on the results of the MUSTT trial.12
However, the non-sustained ventricular tachycardia
had been known before and thus the Holter study
was non-contributory. There were 71 Holter studies
(8.6%) considered to explain syncope. Table 2
summarises these findings. The most common
arrhythmias thought to be consistent with syncope
were high degree AV-block, sick sinus syndrome,
and atrial fibrillation with slow ventricular response.
Two patients had orthodromic reciprocating tachy-
cardia with an accessory pathway, one had AV
nodal re-entry tachycardia. One patient with a
severely depressed LVEF had a pacemaker-mediated
tachycardia, which led to a significant haemo-
dynamic deterioration due to pronounced cardiac
dyssynchrony.
Subgroups
Table 3 shows the diagnostic yield in the five pre-
specified subgroups. Structural heart disease, LVEF
and age were significant predictors of a diagnostic
Holter study, whereas gender and cardiac medica-
tion were not.
Table 4 shows the increasing diagnostic yield of
Holter monitoring with age (p<0.005). The mean
LVEF in all the age groups, including all subgroups
of patients with and without structural heart disease,
was 52% or higher.
In 107 patients (13%) with a prior myocardial
infarction (LVEF 44% 12%), there were 15 diag-
nostic Holter studies (14%), in one case document-
ing ventricular tachycardia. Only 3% of all patients
(n¼28) had an LVEF <35%. Of these, six (21%)
had a Holter study explaining syncope; none was
due to ventricular arrhythmia.
Table 1 Baseline characteristics
Total number of patients 826
Age (years) 72 15
Females 445 (54%)
Structural heart disease 375 (45%)
LVEF 57 10
Cardiac medication
Aspirin 322 (39%)
Anticoagulation 124 (15%)
ACE-inhibitor/Angiotensin II
receptor blockers
306 (37%)
Betablockers 273 (33%)
Verapamil/Diltiazem 33 (4%)
Diuretics 256 (31%)
Amiodarone 41 (5%)
Sotalol 8 (1%)
Class I anti-arrhythmic drugs 0 (0%)
Digoxin 25 (3%)
Data are meansSD or numbers (%) as appropriate. LVEF,
left ventricular ejection fraction, known in 626 patients.
451
191
97
49
7 7 24
0
200
400
600
No
 SH
D
CA
D
HH
D
VH
D
H(O
)CM DC
M
oth
er
Figure 1. Prevalence and types of structural heart disease
(SHD) in the studied patient population. Of the patients
with CAD, 56% (107/191) had documented myocardial
infarction. Three patients with pulmonary heart disease
(cor pulmonale), one with a status after myocarditis and
20 with unclassified cardiomyopathy were included in the
category of ‘other’ structural heart disease. CAD, coronary
artery disease; HHD, hypertensive heart disease; VHD,
valvular heart disease; H(O)CM, hypertrophic (obstruc-
tive) cardiomyopathy; DCM, dilated cardiomyopathy.
Table 2 Results of Holter monitoring (n¼ 826)
Normal 714 (86.4%)
Abnormal not explaining syncope 41 (5.0%)
Abnormal explaining syncope
Total 71 (8.6%)
AVB 19 (2.3%)
SSS 16 (1.9%)
AVB with SSS 4 (0.5%)
AF with SVR 19 (2.3%)
AF with RVR 8 (1.0%)
SVT 3 (0.4%)
VT 1 (0.1%)
PMT 1 (0.1%)
Data are numbers (%). AVB, atrioventricular block; SSS,
sick sinus syndrome; AF, atrial fibrillation; SVR, slow
ventricular response; RVR, rapid ventricular response;
SVT/VT, supraventricular/ventricular tachycardia; PMT,
pacemaker-mediated tachycardia.
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In a comparison of the 345 patients aged 460
years with structural heart disease to the 119 aged
<60 years without structural heart disease, we found
a diagnostic Holter study in 41 (12%) vs. 2 (2%)
of the patients (p<0.001). In a subgroup of
73 female patients aged <60 years, there were no
diagnostic Holter studies, nor were there any in
the 42 patients aged 40 years or younger. However,
there were 8 (20%) Holter studies explaining
syncope in the 41 patients aged 490 years
(p<0.0001).
Impact on therapy
Patients with a diagnostic Holter study
In 58/71 (82%) patients with a Holter study explai-
ning syncope, the symptoms were due to brady-
cardia. Of these, 45 (78%) received a pacemaker;
three with sick sinus syndrome became asympto-
matic when their negative chronotropic drug was
discontinued. Ten patients who were supposed
to receive a pacemaker did not receive it due to
unknown reasons or denied implantation of a
device. The three patients with a supraventricular
tachycardia underwent successful radiofrequency
catheter ablation. Atrial fibrillation with rapid ven-
tricular response was treated with rate control in
seven patients and rhythm control in one. The only
patient with sustained ventricular tachycardia was
empirically prescribed amiodarone, as he refused
the implantation of an ICD. The pacemaker-
mediated tachycardia was relieved by reprogram-
ming the device.
Patients with a non-diagnostic Holter study
Out of the 755 patients with a Holter study
considered unlikely to explain syncope or normal,
33 patients (4.4%) had recurrent syncope and
subsequently received a device 7 months (median)
after the index Holter study. This rate is not different
to the 5.4% of patients receiving a pacemaker on
the basis of a Holter study explaining syncope
(p¼ 0.32). Five patients received the pacemaker
based on the result of an implantable or external
loop recorder, 26 received a device (24 pace-
makers, 2 ICDs) due to a documented arrhythmia on
a resting 12-lead ECG, and two received a pace-
maker because of further unexplained syncopes.
Follow-up of patients who received
a device
Of the 78 patients who had either received a device
due to the first diagnostic Holter study or during
follow-up, 34 had died by December 2006 and
two could not be contacted. None of the remaining
42 patients experienced further syncopes after
device implantation.
Table 3 Subgroup analysis: impact of presence or
absence of different parameters on diagnostic yield of
Holter monitoring
Present Absent p
Structural
heart disease
45/375 (12.0%) 28/451 (6.2%) 0.007
Male gender 40/381 (10.5%) 31/445 (6.7%) 0.07
Age460 years 67/675 (9.9%) 4/151 (2.6%) 0.004
LVEF <50% 19/132 (14.4%) 35/494 (7.1%) 0.008
Cardiac
medication
68/757 (9.0%) 3/69 (4.3%) 0.19
Data are numbers of Holter studies explaining syncope in
relation to the number of patients tested in the individual
subgroup, and the corresponding percentage.
Table 4 Diagnostic yield of Holter monitoring in
patients with and without structural heart disease (SHD)
in different age groups
SHD Patients Diagnostic
Holter studies
440 years
All 42 0 (0%)
No 39 0 (0%)
Yes 3 0 (0%)
41–50 years
All 33 1 (3%)
No 29 0 (0%)
Yes 4 1 (25%)
51–60 years
All 79 3 (4%)
No 53 2 (4%)
Yes 26 1 (4%)
61–70 years
All 128 7 (5%)
No 59 2 (3%)
Yes 69 5 (7%)
71–80 years
All 273 24 (9%)
No 153 12 (8%)
Yes 120 12 (10%)
81–90 years
All 230 28 (12%)
No 100 7 (7%)
Yes 130 21 (16%)
490 years
All 41 8 (20%)
No 18 5 (28%)
Yes 23 3 (13%)
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Discussion
Main findings
In our population of 826 patients referred for
the evaluation of syncope, the overall diagnostic
yield of Holter monitoring was 8.6%. The diagnostic
yield varied greatly among subgroups; the presence
of structural heart disease, depressed LVEF and
advanced age were predictors for a diagnostic
Holter result. The frequency with which patients
received either a pacemaker or an ICD based on
Holter results was similar to that of the patients
who underwent device implantation after further
syncopes during follow-up. None of the patients
with a device experienced further syncope during
follow-up, suggesting that the events leading to
implantation had truly been arrhythmogenic.
As 63% of patients with a Holter study considered
to explain syncope received a pacemaker, it could
be argued that the impact of Holter monitoring on
device implantation is considerable if the Holter
study is diagnostic. However, in the whole popula-
tion, nearly 10% of the patients received a device,
with similar percentages based on the index Holter
study (5.4%) and after further syncopes during
follow-up (4.4%). This demonstrates the low addi-
tional impact of Holter monitoring on device
implantation, a finding that has not been shown in
previous studies.
Previous studies
Finding the cause of syncope may often pose
a challenge even for the experienced clinician.
Although the evaluation of syncope frequently leads
to excessive use of diagnostic tests, no diagnosis
is made in 25 to 50% of patients.7,11,13,14
Several guidelines for the diagnostic evaluation of
syncope have been published. However, they
frequently do not relate well to clinical practice.15,16
An important problem of Holter monitoring is
that the symptom (syncope) seldom occurs during
monitoring, and hence the recording of an arrhyth-
mia that could potentially explain syncope is freq-
uently used as the diagnostic criterion. One study
found that an arrhythmia-related symptom (syncope
or presyncope) during Holter monitoring was pre-
sent only in 2% of patients, and more subjects (15%)
had syncope or presyncope without an associated
arrhythmia, which in fact might be considered a
negative diagnostic clue.17 In one recent study,
the diagnostic yield of 24-h Holter monitoring
(defined as the correlation of serious arrhythmias
with syncope or near-syncope) was 6%, reaching
12% when restricted to high-risk patients with
structural heart disease and/or an abnormal ECG.18
The results of the latter study are reflected in our
data, with a similar diagnostic yield overall as well
as in patients with structural heart disease. However,
we studied the diagnostic yield in various subgroups
and had a much wider range of 0 to 20%. Previous
studies on Holter monitoring focused on younger
patients, and included subjects with presyncope
and dizziness. Given the relatively old age of our
patient population, our data might even overesti-
mate the diagnostic yield of Holter monitoring when
applied to a younger population.17,19
The role of loop recorders
The optimal duration of Holter monitoring has also
been questioned. There is evidence suggesting that
monitoring for 24 h may not be enough to identify
important arrhythmias in patients with syncope,
especially in selected patient groups. Monitoring
may need to be extended to 48 h if the first 24 h of
monitoring is normal.19 It seems obvious that this
strategy potentially identifies more, but certainly not
all relevant arrhythmias. ‘The longer, the better’
seems a logical approach, and it is not surprising
that a prolonged monitoring strategy using an
implantable loop recorder is even more likely to
provide a diagnosis in patients with unexplained
syncope than testing with an external loop
recorder;20 however, the setting in which this
approach would still be cost-effective remains
to be determined. Recently, a cost-effectiveness
analysis of a randomised trial comparing external
loop recorders to Holter monitoring in the evalua-
tion of ‘community-acquired’ syncope, showed that
external loop recorders can be an economically
attractive alternative because of their markedly
increased diagnostic yield.21 In our population,
a prolonged monitoring strategy (external or
implanted loop recorder) provided a diagnosis of
a significant arrhythmia in only 5 of the 33 patients
(15%) who received a device despite a negative
index Holter study. This demonstrates that such
an approach results in an aetiological diagnosis
in some, but far from all cases, and a device was
implanted in a much higher percentage of cases due
to an arrhythmia documented on a 12-lead ECG.
Subgroups
As cardiac arrhythmias are mostly intermittent
and intervals vary greatly, a normal Holter study
certainly does not rule out an arrhythmic cause of
syncope. Holter monitoring should not be used as
a screening tool in patients with possible syncope,
since its diagnostic value is limited, especially
without proper patient selection.22 This is empha-
sised by the results of our analysis, in which
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we found dramatic differences in its diagnostic value
between subgroups. The diagnostic yield was very
low in patients aged <60 years without structural
heart disease (1.7%) and absent in female patients
aged <60 years, as well as in all patients aged
<40 years.
For widely available testing modalities such as
Holter monitoring, patient selection is crucial in
order to reach an acceptable diagnostic yield.
This could be achieved at least to some degree
by screening for the presence of structural heart
disease. In one study, an abnormal resting 12-lead
ECG proved useful as a screening tool to select
patients.23
In our study, LVEF was preserved in patients with
structural heart disease but significantly lower
(53%12%) compared to patients without struct-
ural heart disease (LVEF 61%5%; p<0.0001).
Structural heart disease and depressed LVEF
(<50%) were associated with relatively high diag-
nostic yields of nearly 12% and 14%, respectively.
However, this information may not always be
available. The diagnostic yield was similar when
only focusing on patients with a previous myocar-
dial infarction (14%) and higher (21%) in patients
with an LVEF of <35%. The one case of syncope due
to ventricular tachycardia occurred in the former
group. Ventricular tachyarrhythmias are important
causes of syncope, especially in patients with an
ischaemic cardiomyopathy and patients with signi-
ficantly decreased LVEF. A 24-h Holter monitor
is probably less likely to record ventricular arrhyth-
mias due to their often sporadic nature. Therefore
ventricular tachyarrhythmias might be significantly
underestimated when relying solely on Holter
monitoring to evaluate patients with ischaemic
cardiomyopathy or significantly depressed LVEF
who present with syncope. The assessment of this
patient group warrants a much more comprehensive
evaluation.
Age was a significant predictor of a diagnostic
Holter study, with the highest yield (almost 20%)
in patients older than 90 years. This accords with the
observation that the prevalence of disorders of
the conduction system increases with age. The diag-
nostic yield in patients without structural heart
disease only increased to an above average level
in patients aged490 years. It reached a diagnostic
yield of 8%, the overall average in our patient
population, only above the age of 70 years. Younger
patients and patients without structural heart
disease probably benefit more from a prolonged
monitoring strategy, as discussed above. However,
this depends on the clinical situation, including the
interval between events and the exact history.
Limitations
Our study has several limitations. We report data
from a single centre, and patient selection and thus
diagnostic yield could be affected by referral bias.
Due to the retrospective design, we had to rely upon
referring physicians regarding patient selection.
The question as to whether a given Holter study
was done in a patient with true syncope, a patient
with presumed syncope or even in order to rule out
serious arrhythmia cannot be answered. Although
relatively strict diagnostic criteria were applied, the
absence of a gold standard to validate a diagnostic
study leaves us with some degree of uncertainty
to whether the syncope leading to the Holter study
was in fact caused by the arrhythmia recorded
during monitoring.
Conclusions
The diagnostic yield of Holter monitoring for the
evaluation of syncope and the impact on device
implantation is generally overestimated. In our
population, the likelihood of a diagnostic Holter
study varied greatly between different subgroups,
and was especially low in patients aged <60 years
and/or without structural heart disease. This suggests
that these patients should not undergo Holter
monitoring to evaluate syncope.
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